Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Mar 12;142:155496. doi: 10.1016/j.cyto.2021.155496

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 Elsevier Ltd. All rights reserved.

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

PMC Copyright notice

Fig. 5 — Antiviral activity of Glycyrrhizin against SARS-CoV-2 (a) Effect of Glycyrrhizin on viability of Vero E6 cells. (b-c) Percentage inhibition in replication of SARS-CoV-2 in Vero E6 cells in the presence of increasing concentrations of Glycyrrhizin or 10 μM remdesivir. The graphs represent average values from three independent experiments. Two-tailed paired t-test was used for statistical analysis. p < 0.05 *, p < 0.01 **, p < 0.001 *** (d) Schematic depiction of the multifaceted potential of Glycyrrhizin to inhibit viral replication in Vero E6 cells as well as to ameliorate host-inflammatory responses.